Flanvotumab Biosimilar - Research Grade

Human

TYRP1

>1mg/ml

IgG1 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

P17643

7306

Blue ice

This product (ICH5553) is a recombinant, unconjugated non-therapeutic analog of flanvotumab, a fully human IgG1-kappa monoclonal antibody directed against tyrosinase-related protein 1 (TYRP1, also called TRP1 or gp75). It is supplied for research use only and is not the clinical drug; it is not intended for human or veterinary use. Because TYRP1 is a melanocyte- and melanoma-associated cell-surface antigen, a flanvotumab-analog antibody is a useful reagent for probing TYRP1 biology and for melanoma-focused antibody research. Typical applications include use as a defined, sequence-characterized binder for detecting or capturing surface TYRP1, as a benchmark or isotype-matched reference in binding and effector-function assays, as a positive control in method development, and as a targeting scaffold in ADCC or antibody-drug-conjugate development workflows. The recombinant format gives lot-to-lot consistency. Material is offered at research grade (low endotoxin, typically <1 EU/mg) with ultra-low-endotoxin (<0.5 EU/mg) and bulk milligram-to-gram quantities available to support in-vitro screening and preclinical study designs. TYRP1 (tyrosinase-related protein 1; gene TYRP1, UniProt P17643), historically known as TRP1 or the gp75 antigen, is a type I melanosomal membrane glycoprotein and a member of the tyrosinase family of copper-binding oxidoreductases. It is expressed almost exclusively in melanocytes and melanoma cells, where it localizes to the melanosome and participates in the eumelanin (black-brown pigment) biosynthetic pathway; in human melanocytes it contributes to the later oxidation/stabilization steps and helps maintain melanosome integrity. TYRP1 also physically associates with and stabilizes tyrosinase, protecting melanocytes from tyrosinase-mediated toxicity. Its restricted, lineage-specific expression and presence at the cell surface on melanoma cells make TYRP1 an attractive tumor-associated antigen. Loss-of-function TYRP1 mutations cause oculocutaneous albinism type 3.

DHICA oxidase, Catalase B, Glycoprotein 75, Melanoma antigen gp75, Tyrosinase-related protein 1, TRP, TRP-1, 5 6-dihydroxyindole-2-carboxylic acid oxidase, CAS2, TYRP, TYRRP

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Flanvotumab (anti-TYRP1) Biosimilar

Q: Is the Flanvotumab biosimilar available in bulk or gram quantities?

A: Yes — the Flanvotumab biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is this research-grade Flanvotumab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Flanvotumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Flanvotumab that binds TYRP1.